10-K: AEON Biopharma 10-K Filing Reveals Going Concern Doubts Amidst Pipeline Progress

AEON Biopharma's annual 10-K filing highlights concerns about its ability to continue as a going concern, despite ongoing clinical trials for its lead product candidate, ABP-450.

Summary

• AEON Biopharma, a clinical-stage company, is focused on developing ABP-450 for debilitating medical conditions.
• The company has completed a Phase 2 study for cervical dystonia and is conducting a Phase 2 study for migraine.
• Topline data from the episodic migraine cohort of the Phase 2 study was reported in October 2023, showing statistical significance on multiple secondary endpoints but not the primary endpoint.
• An interim readout of topline data related to the chronic cohort of the Phase 2 migraine study is expected in the second quarter of 2024, with full topline data in the third quarter of 2024.
• The company has exclusive rights to ABP-450 for therapeutic uses in key markets.
• AEON has incurred significant losses since inception, with an accumulated deficit of $473.6 million as of December 31, 2023.
• Management has expressed substantial doubt about the company's ability to continue as a going concern due to uncertainties around raising additional capital.
• The company expects to have sufficient cash to fund operations through June 2024, including $15 million of committed financing from Daewoong.
• Additional funding will be required for further development of ABP-450, including Phase 3 trials, which may not be available on reasonable terms or at all.

Sentiment

Score: 3

Explanation: The document highlights significant financial risks and uncertainties, including going concern doubts and the failure of a key clinical trial to meet its primary endpoint. While there are some positive aspects, such as the potential of ABP-450 and the company's exclusive rights, the overall sentiment is negative due to the financial instability and clinical setbacks.

Positives

• ABP-450 has shown positive results in a Phase 2 study for cervical dystonia.
• The company has exclusive rights to ABP-450 for therapeutic uses in key markets.
• The company has a management team with experience in botulinum toxin development and commercialization.
• The company has a patented injection protocol for migraine treatment.
• The company is pursuing an original BLA for therapeutic indications of ABP-450, which could improve reimbursement.

Negatives

• The company has incurred significant losses since inception and has an accumulated deficit of $473.6 million.
• The Phase 2 clinical trial for episodic migraine did not meet its primary endpoint.
• The company's future success depends entirely on the successful and timely regulatory approval and commercialization of ABP-450.
• The company has concluded that there is substantial doubt about its ability to continue as a going concern.
• The company will require additional capital to fund its future operations, which may not be available on acceptable terms or at all.

Risks

• The company's ability to raise additional capital is uncertain.
• The company's future success depends entirely on the successful and timely regulatory approval and commercialization of ABP-450.
• Clinical product development is a lengthy, expensive, and uncertain process.
• Even if approved, ABP-450 may not achieve broad market acceptance.
• The company faces significant competition in the botulinum toxin market.
• The company relies on a single supplier, Daewoong, for manufacturing ABP-450.
• The company is subject to extensive government regulation.
• The price of the company's common stock may be volatile.
• Sales of a substantial number of the company's securities could cause the price of the common stock and warrants to fall.
• The company is subject to stringent and often unsettled privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security.

Future Outlook

The company expects to continue to incur significant expenses and increasing net operating losses for the foreseeable future as it seeks regulatory approval and prepares for commercialization of ABP-450. The company expects to have sufficient cash to fund operations through June 2024, including $15 million of committed financing from Daewoong. Additional funding will be required for further development of ABP-450, including Phase 3 trials, which may not be available on reasonable terms or at all.

Management Comments

• Management has concluded that uncertainties around our ability to raise additional capital raise substantial doubt about our ability to continue as a going concern.
• We are actively attempting to secure additional capital to fund our operations.

Industry Context

The global therapeutic botulinum toxin market is projected to grow to $4.4 billion in 2027, with the United States being the largest market. The company is targeting the migraine, cervical dystonia, and gastroparesis markets, which represent a significant opportunity.

Comparison to Industry Standards

• The company's main competitors in the botulinum toxin market are Botox, Dysport, and Xeomin, which collectively held over 98% of the US therapeutic market in 2021.
• Botox, marketed by AbbVie, had approximately 85% of the global therapeutic market share and 95% of the US market share in 2019.
• The company's ABP-450 has a similar 900 kDa molecular weighting to Botox, which the company believes will facilitate physician adoption.
• The company's patented injection protocol for migraine treatment differentiates it from Botox.
• The company is seeking an original BLA for therapeutic indications of ABP-450, which could provide a competitive advantage over other botulinum toxins that have both cosmetic and therapeutic indications.

Legal Proceedings

• Odeon Capital Group LLC has filed a lawsuit against the company, alleging failure to pay a deferred underwriting fee of $1.25 million.

Related Party Transactions

• The company has a license and supply agreement with Daewoong Pharmaceutical Co. Ltd.
• The company has a subscription agreement with Daewoong relating to the sale and issuance of senior secured convertible notes.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's financial instability.
• Employees may be affected by potential cost-cutting measures or restructuring due to the company's financial challenges.
• Customers and patients may experience delays or disruptions in the development and availability of ABP-450.
• Suppliers and creditors may face increased risk of non-payment due to the company's financial instability.

Next Steps

• The company plans to announce an interim readout of topline data related to the chronic cohort of its Phase 2 migraine study in the second quarter of 2024.
• The company plans to release full topline data from the chronic cohort of its Phase 2 migraine study in the third quarter of 2024.
• The company is in discussions with the FDA regarding the design of its Phase 3 study in cervical dystonia, which it expects to commence based on the availability of capital resources.
• The company continues to evaluate various pathways to most efficiently advance its clinical development program for gastroparesis.

Key Dates

Keywords

ABP-450, botulinum toxin, migraine, cervical dystonia, gastroparesis, clinical trials, regulatory approval, biopharmaceutical, Daewoong, going concern